StockData
Pulsenmore Ltd. logo

Pulsenmore Ltd. (PLSM) stock

PLSMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 30, 2026Score 3/30
$1.47−0.08 (-5.16%)

Close on Nov 12, 2026Market cap $9.56MP/E 1.9Yield –

Pulsenmore Ltd. grew revenue 314.3% to 40.02M ILS over fiscal 2025. Free cash flow was -33.01M ILS. At the latest close the market valued the company at 30.32M ILS, 1.9 times its earnings.

Revenue
40.02M ILS
+314.3% vs. a year earlier
Free cash flow
-33.01M ILS
FY2025
EPS, diluted
2.46 ILS
-57.3% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
30.32M ILS
P/E ratio
1.9
Price to sales
0.76
Price to book
–
Dividend yield
–
Free cash flow yield
-108.88%

Fundamentals

Revenue
40.02M ILS
EPS, diluted
2.46 ILS
Free cash flow
-33.01M ILS

Trading

Previous close
$1.55
Open
$1.56
Day's range
$1.43 – $1.56
Volume
6,156
Average volume (20 days)
18,783
RSI (14 days)
35.0
Volatility (1 year)
130.7%
Relative volume
0.06×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodPLSMS&P 500DifferencePLSM per yearS&P 500 per year
1 month-19.2%-2.7%−16.5 pts
3 months-52.1%-1.7%−50.4 pts

Four years at a glance

Fiscal years 2022 to 2025, ILS

Revenue

40.02M ILS+314.3% YoY

Gross profit

33.68M ILS+841.6% YoY

EPS, diluted

2.46 ILS-57.3% YoY

Free cash flow

-33.01M ILS
Reported period

Press releases

Releases Pulsenmore filed with the SEC as exhibits to Form 8-K or 6-K

  1. Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer
    6-K
  2. Expands Its Fertility Platform into the UK
    6-K
  3. Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring
    6-K
  4. 6-K exhibit EX-99.1
    6-K
  5. following discussion and analysis of our operating and financial condition and prospects provides information that we believe to
    6-K
  6. Ltd. Announces Financial Results and Business Highlights for the First Half of 2026
    6-K
All press releases and earnings

About Pulsenmore

Surgical & Medical Instruments & Apparatus

Pulsenmore Ltd. is a medical device company that develops, manufactures, and markets portable, non-invasive ultrasound solutions designed for home use. The company offers two main products, the Pulsenmore ES and Pulsenmore FC, while also developing the Pulsenmore MC and an assisted service for conducting biophysical profile tests in high-risk pregnancies. Its technology enables home-based ultrasound scans across obstetrics and gynecology, with applications extending to pulmonary medicine, cardiology, and urology. Pulsenmore provides its solutions primarily to healthcare organizations and patient end-users, including an ongoing commercial relationship with Clalit Health Services.

Company profile, executives and history

Pulsenmore stock: common questions

What is Pulsenmore's stock price?

PLSM closed at $1.47 on Nov 12, 2026, down 5.16% on the day.

What is Pulsenmore's market cap?

Pulsenmore was worth $9.56M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

What is PLSM's P/E ratio?

PLSM trades at 1.9 times earnings, based on diluted earnings per share of 2.46 ILS over fiscal 2025.

How much revenue does Pulsenmore make?

Pulsenmore reported revenue of 40.02M ILS for fiscal 2025, up 314.3% from a year earlier.

Does Pulsenmore pay a dividend?

No. Pulsenmore has not paid a cash dividend over the last twelve months.

Who are Pulsenmore's competitors?

Companies most similar to Pulsenmore by business, industry and size include UTMD, PROF, BWAY, SNWV, CVRX.

See a number that looks wrong?